Scarica l'app Stockscreener
35.51
1.15%
0.405
Dopo l'orario di chiusura:
35.51
0.005
+0.01%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SUPN Giù?
Forum
Previsione
Precedente Chiudi:
$35.10
Aprire:
$34.66
Volume 24 ore:
858.51K
Relative Volume:
1.38
Capitalizzazione di mercato:
$1.99B
Reddito:
$651.97M
Utile/perdita netta:
$59.71M
Rapporto P/E:
33.19
EPS:
1.0696
Flusso di cassa netto:
$172.03M
1 W Prestazione:
+5.73%
1M Prestazione:
+11.58%
6M Prestazione:
-7.47%
1 anno Prestazione:
+20.07%
Intervallo 1D:
$34.64
$35.69
Intervallo di 1 settimana:
$32.83
$35.92
Portata 52W:
$27.05
$40.28
Supernus Pharmaceuticals Inc Stock (SUPN) Company Profile
Nome
Supernus Pharmaceuticals Inc
Settore
Telefono
301-838-2500
Indirizzo
9715 KEY WEST AVENUE, ROCKVILLE, MD
Confronta SUPN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SUPN
Supernus Pharmaceuticals Inc
|
35.51 | 1.97B | 651.97M | 59.71M | 172.03M | 1.0696 |
|
ZTS
Zoetis Inc
|
147.38 | 64.91B | 9.29B | 2.52B | 2.28B | 5.57 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.16 | 43.33B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
HLN
Haleon Plc Adr
|
9.66 | 42.36B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
15.38 | 17.72B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
294.28 | 12.42B | 2.99B | 1.21B | 1.13B | 25.06 |
Supernus Pharmaceuticals Inc Stock (SUPN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-30 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2025-02-19 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2025-01-06 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-09-11 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2023-01-03 | Ripresa | Jefferies | Buy |
| 2021-12-01 | Ripresa | Jefferies | Buy |
| 2021-04-13 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-06-16 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2020-06-15 | Ripresa | Jefferies | Hold |
| 2019-11-08 | Downgrade | Berenberg | Buy → Hold |
| 2019-11-07 | Downgrade | Stifel | Buy → Hold |
| 2019-11-06 | Downgrade | Jefferies | Buy → Hold |
| 2018-11-12 | Reiterato | B. Riley FBR | Buy |
| 2018-01-18 | Reiterato | B. Riley FBR, Inc. | Buy |
| 2017-12-28 | Reiterato | B. Riley FBR, Inc. | Buy |
| 2017-12-04 | Aggiornamento | Janney | Neutral → Buy |
| 2017-11-08 | Aggiornamento | Stifel | Hold → Buy |
| 2017-10-19 | Iniziato | FBR & Co. | Buy |
| 2017-09-19 | Downgrade | Stifel | Buy → Hold |
| 2017-07-17 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2017-07-14 | Iniziato | Janney | Neutral |
| 2017-06-01 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2016-07-18 | Downgrade | Northland Capital | Outperform → Market Perform |
| 2016-07-18 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2016-02-08 | Aggiornamento | Jefferies | Hold → Buy |
| 2015-11-05 | Reiterato | Northland Capital | Outperform |
| 2015-10-28 | Iniziato | Northland Capital | Outperform |
Mostra tutto
Supernus Pharmaceuticals Inc Borsa (SUPN) Ultime notizie
Supernus strengthens neuropsychiatric portfolio with Sage Therapeutics - Yahoo Finance
What institutional investors are buying Supernus Pharmaceuticals Inc. stockStock Market Entry Points To Watch Now - jammulinksnews.com
Supernus completes acquisition of Sage Therapeutics for $8.50 per share By Investing.com - Investing.com South Africa
Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics - GlobeNewswire
Supernus' $200M Sage Therapeutics Acquisition Adds First-Ever Oral Postpartum Depression Drug - Stock Titan
When is Supernus Pharmaceuticals Inc. stock expected to show significant growthFinancial News Entry Points Backed By Experts - jammulinksnews.com
Supernus Pharmaceuticals Stock Gains on Upgrade and Acquisition ProgressNews and Statistics - IndexBox
Cantor Fitzgerald upgrades Supernus Pharmaceuticals stock rating on Qelbree sales outlook - Investing.com Canada
Why Supernus Pharmaceuticals (SUPN) Stock Is Up Today - FinancialContent
Supernus Pharmaceuticals Announces Expiration of - GlobeNewswire
What are the latest earnings results for Supernus Pharmaceuticals Inc.Capitalize on emerging investment opportunities - jammulinksnews.com
Supernus announces expiration of HSR waiting period for Sage Therapeutics - TipRanks
Supernus-Sage acquisition clears antitrust hurdle as HSR waiting period expires - Investing.com India
Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Sage Therapeutics, Inc. Tender Offer - GlobeNewswire
Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Sage Therapeutics, Inc. Tender Offer - Benzinga
Supernus-Sage $12B Merger Gets Key Regulatory Green Light as Tender Offer Deadline Nears - Stock Titan
What is the dividend policy of Supernus Pharmaceuticals Inc. stockAchieve superior capital gains with smart trades - jammulinksnews.com
Is Supernus Pharmaceuticals Inc. a growth stock or a value stockMaximize portfolio growth with strategic plans - jammulinksnews.com
How many analysts rate Supernus Pharmaceuticals Inc. as a “Buy”Free Risk Assessment Services - jammulinksnews.com
What are the technical indicators suggesting about Supernus Pharmaceuticals Inc.Unlock powerful market analysis and alerts - jammulinksnews.com
Why is Supernus Pharmaceuticals Inc. stock attracting strong analyst attentionAccess exclusive market insights for free - jammulinksnews.com
Can Mixed Fundamentals Have A Negative Impact on Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Current Share Price Momentum? - 富途牛牛
What institutions are buying Supernus Pharmaceuticals Inc. stock nowBreakthrough stock performance - jammulinksnews.com
What drives Supernus Pharmaceuticals Inc. stock priceDouble or triple returns - PrintWeekIndia
What analysts say about Supernus Pharmaceuticals Inc. stockRapid wealth creation - Autocar Professional
Branded Pharmaceuticals Stocks Q1 Recap: Benchmarking Supernus Pharmaceuticals (NASDAQ:SUPN) - FinancialContent
What makes Supernus Pharmaceuticals Inc. stock attractive to long term investorsBreakout portfolio performance - jammulinksnews.com
Supremex Announces Date of Its 2025 Second Quarter Results Conference Call - Yahoo.co
Is Supernus Pharmaceuticals Inc. a good long term investmentExtraordinary performance - Autocar Professional
Supernus Pharmaceuticals Inc. Stock Analysis and ForecastStrong return on investment - Autocar Professional
Benign Growth For Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Underpins Its Share Price - simplywall.st
Supernus Pharmaceuticals (NASDAQ:SUPN) Cut to "Hold" at Wall Street Zen - MarketBeat
Published on: 2025-07-23 12:28:32 - Autocar Professional
Supernus Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 5 - Nasdaq
Supernus Pharmaceuticals to Announce Second Quarter 2025 - GlobeNewswire
SUPN SEC FilingsSupernus Pharma 10-K, 10-Q, 8-K Forms - Stock Titan
Supernus Pharmaceuticals to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 5, 2025 - Yahoo.co
Supernus Pharmaceuticals Inc Azioni (SUPN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Supernus Pharmaceuticals Inc Azioni (SUPN) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| DEC TIMOTHY C | Senior Vice-President & CFO |
Mar 10 '25 |
Option Exercise |
0.00 |
3,800 |
0 |
13,636 |
| Khattar Jack A. | President, CEO |
Mar 07 '25 |
Option Exercise |
0.00 |
38,640 |
0 |
992,219 |
| Mottola Frank | SVP, Quality, GMP, Ops, IT |
Mar 07 '25 |
Option Exercise |
0.00 |
2,625 |
0 |
16,507 |
| Mottola Frank | SVP, Quality, GMP, Ops, IT |
Feb 26 '25 |
Option Exercise |
0.00 |
5,760 |
0 |
17,683 |
| Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Feb 21 '25 |
Option Exercise |
0.00 |
1,650 |
0 |
11,799 |
| Rubin Jonathan | SVP, Chief Medical Officer |
Feb 21 '25 |
Option Exercise |
0.00 |
1,875 |
0 |
8,780 |
| Rubin Jonathan | SVP, Chief Medical Officer |
Feb 21 '25 |
Sale |
39.15 |
927 |
36,292 |
7,853 |
| Mottola Frank | SVP, Quality, GMP, Ops, IT |
Feb 21 '25 |
Option Exercise |
0.00 |
1,125 |
0 |
9,576 |
| Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Feb 04 '25 |
Option Exercise |
29.61 |
9,477 |
280,614 |
19,626 |
| Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Feb 04 '25 |
Sale |
39.70 |
9,477 |
376,237 |
10,149 |
0.87%
0.80%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):